Photo by impulsq from unsplash
Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II… Click to show full abstract
Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
Keywords:
updates management;
cancer;
management kidney;
kidney cancer;
histology
Journal Title: Journal of the National Comprehensive Cancer Network : JNCCN
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the National Comprehensive Cancer Network : JNCCN
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!